Drug Profile
AUM 001
Alternative Names: AUM-001; ETC 206; ETC-1907206Latest Information Update: 21 Aug 2023
Price :
$50
*
At a glance
- Originator Agency for Science, Technology and Research; Duke-NUS Graduate Medical School Singapore
- Developer AUM Biosciences
- Class Antineoplastics
- Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
- No development reported Chronic myeloid leukaemia; Haematological malignancies; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Jun 2023 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 25th World Congress on Gastrointestinal Cancer (WCGC-2023)
- 02 Jun 2023 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 14 Apr 2023 Phase-II clinical trials in Colorectal cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in Australia (PO) (NCT05462236)